Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-TM4SF1 CAR-T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) transmembrane 4 L six family member 1 (TM4SF1) and containing a safety/kill switch composed of a truncated form of the human epidermal growth factor receptor (ErbB1t; EGFRt HER1t), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-TM4SF1 CAR-T cells specifically recognize and bind to TM4SF1-expressing tumor cells, resulting in tumor cell lysis. TM4SF1 plays a key role in the regulation of cell development, activation, growth and motility, and is overexpressed by a variety of tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TM4SF1-CAR-expressing autologous T cells
autologous TM4SF1-CAR T cells
autologous TM4SF1-positive CAR T cells
autologous TM4SF1-positive CAR-T cells
TM4SF1-CAR-expressing autologous T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search